Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

Watch recent Medigene’s webinar, Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies. This R&D event focuses on its optimal 3S (specific, sensitive and safe) T cell receptors for T cell receptor-guided precision immunotherapies, including its lead programme MDG1015.

Panellists

Dr Selwyn Ho, CEO at Medigene

Dr Selwyn Ho is a seasoned healthcare executive, with over 25 years of international experience spanning Europe, the US and Asia. He has held senior leadership roles in both private and publicly traded biotech and pharmaceutical companies, with a focus on inflammation and immunology. Dr Ho became CEO of Medigene in July 2022, after serving as chief business officer at Connect Biopharma and executive-in-residence at New Rhein Healthcare Investors. He holds a medical degree (MB BS) and a BSc in pharmacology from Imperial College London, alongside post-graduate qualifications in pharmaceutical medicine from the Royal College of Physicians, UK.

Prof Dolores Schendel, CSO at Medigene

Professor Dolores Schendel is a leading expert in T cell research and immunotherapy, with decades of experience and nearly 200 scientific publications. She has served on the scientific review boards of prestigious organisations, including the German Research Foundation and the European Research Council. Since 2022, Professor Schendel has been the chief scientific officer of Medigene, a role she previously held after Medigene acquired her company, Trianta Immunotherapies, in 2014. From 1998 to 2013, she was the director of the Institute of Molecular Immunology at the German Research Centre for Environmental Health in Munich. Her work has significantly contributed to advancing immunotherapy treatments.

Dr Kirsty Crame, VP Clinical Development at Medigene

Dr Kristy Crame is a Doctor of Medicine, with over 10 years of experience in the biotech industry, including six years specialising in cell therapy. Currently the vice president of clinical research and development at Medigene, Dr Crame has held key roles at Gadeta, including director of clinical development and clinical programme manager. She has also served as COO and programme manager at Diaqua. Dr Crame earned her medical degree from the University of Amsterdam.

Dr Barbara Loesch, Head of Technology & Innovation Department at Medigene

Dr Barbara Loesch, a trained biologist, brings over 18 years of experience in adoptive immune cell therapy (Immunis). She joined Medigene Immunotherapies in 2018 and currently serves as the head of the technology and innovation department. Dr Loesch holds a PhD from the Helmholtz Centre in Munich, where she developed her expertise in immunotherapy and biotechnology.

Dr David Zhen, Principal Investigator at Medigene

Dr David Zhen is an associate professor of medicine at Fred Hutchinson Cancer Center and the University of Washington, and co-director of the neuroendocrine tumour programme. Dr Zhen’s research focuses on developing new therapies for gastroesophageal and neuroendocrine cancers through clinical trials and translational research to identify biomarkers predicting immunotherapy response. Dr Zhen serves on several national committees, including the National Comprehensive Cancer Network’s neuroendocrine and adrenal tumours guidelines panel, the National Cancer Institute’s (NCI’s) neuroendocrine tumour and gastroesophageal task forces and plays an active role in the SWOG and NCI cooperative group systems.